PL2895600T3 - Peptydy UBE2T i szczepionki je zawierające - Google Patents

Peptydy UBE2T i szczepionki je zawierające

Info

Publication number
PL2895600T3
PL2895600T3 PL13837757T PL13837757T PL2895600T3 PL 2895600 T3 PL2895600 T3 PL 2895600T3 PL 13837757 T PL13837757 T PL 13837757T PL 13837757 T PL13837757 T PL 13837757T PL 2895600 T3 PL2895600 T3 PL 2895600T3
Authority
PL
Poland
Prior art keywords
same
vaccines containing
ube2t
peptides
ube2t peptides
Prior art date
Application number
PL13837757T
Other languages
English (en)
Polish (pl)
Inventor
Takuya Tsunoda
Ryuji Osawa
Sachiko Yoshimura
Tomohisa Watanabe
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of PL2895600T3 publication Critical patent/PL2895600T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019—Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
PL13837757T 2012-09-11 2013-09-09 Peptydy UBE2T i szczepionki je zawierające PL2895600T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261699550P 2012-09-11 2012-09-11
PCT/JP2013/005321 WO2014041784A1 (en) 2012-09-11 2013-09-09 Ube2t peptides and vaccines containing the same
EP13837757.7A EP2895600B1 (en) 2012-09-11 2013-09-09 Ube2t peptides and vaccines containing the same

Publications (1)

Publication Number Publication Date
PL2895600T3 true PL2895600T3 (pl) 2020-10-05

Family

ID=50277926

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13837757T PL2895600T3 (pl) 2012-09-11 2013-09-09 Peptydy UBE2T i szczepionki je zawierające

Country Status (17)

Country Link
US (2) US10092634B2 (enExample)
EP (1) EP2895600B1 (enExample)
JP (1) JP6283861B2 (enExample)
KR (1) KR102110873B1 (enExample)
CN (2) CN104619833B (enExample)
AU (1) AU2013317194B2 (enExample)
BR (1) BR112015004349B1 (enExample)
CA (1) CA2873155C (enExample)
DK (1) DK2895600T3 (enExample)
ES (1) ES2784862T3 (enExample)
IL (1) IL236690B (enExample)
MX (1) MX362912B (enExample)
PL (1) PL2895600T3 (enExample)
RU (1) RU2663350C2 (enExample)
SG (2) SG11201501761SA (enExample)
TW (1) TWI632162B (enExample)
WO (1) WO2014041784A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12098387B2 (en) 2015-10-19 2024-09-24 University Of Maryland, Baltimore Methods for generating engineered human primary blood dendritic cell lines
JP6715004B2 (ja) 2015-12-25 2020-07-01 宏 半田 免疫賦活化剤およびその製造方法
BR112019014917A2 (pt) 2017-01-25 2020-03-31 Ose Immunotherapeutics Método para fabricar uma emulsão estável para entrega de peptídeo
AU2018346765B2 (en) * 2017-10-06 2025-02-06 Oncotherapy Science, Inc. Screening of T lymphocytes for cancer-specific antigens
KR102322832B1 (ko) * 2019-04-22 2021-11-12 한국과학기술연구원 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113679829B (zh) 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
ATE375362T1 (de) 1998-06-25 2007-10-15 Kyogo Itoh Von cyclophilin b abstammende tumorantigen- peptide
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
CZ20011049A3 (cs) 1998-10-05 2002-08-14 Pharmexa A/S Imunogenní kompozice a způsob selekce imunogenního analogu
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
CA2417570C (en) 2000-07-31 2010-12-07 Kyogo Itoh Tumor-specific t cell activation by peptide antigens
US20070202109A1 (en) 2003-09-24 2007-08-30 Oncotherapy Science, Inc. Method Of Diagnosing Breast Cancer
JP4579246B2 (ja) 2003-09-24 2010-11-10 オンコセラピー・サイエンス株式会社 乳癌を診断する方法
WO2008102906A1 (en) 2007-02-20 2008-08-28 Oncotherapy Science, Inc. Hspc-hrpc transition genes
TWI596109B (zh) 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
TW200908998A (en) * 2007-06-27 2009-03-01 Oncotherapy Science Inc Compositions and methods of treating cancer
CN102215870B (zh) * 2008-09-18 2013-11-20 学校法人庆应义塾 癌症的诊断方法和治疗方法
TWI500932B (zh) 2008-12-05 2015-09-21 Oncotherapy Science Inc Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
EP2382314A4 (en) * 2008-12-24 2013-03-06 Oncotherapy Science Inc C1ORF59 PEPTIDES AND VACCINES CONTAINING THEM
TW201102081A (en) * 2009-05-11 2011-01-16 Oncotherapy Science Inc TTK peptides and vaccines including the same
TW201216982A (en) * 2010-10-21 2012-05-01 Oncotherapy Science Inc WDHD1 peptides and vaccines including the same
RU2013123038A (ru) * 2010-10-21 2014-11-27 Онкотерапи Сайенс, Инк. Пептиды с18orf54 и вакцины, включающие их
AU2011336019B2 (en) * 2010-12-02 2016-07-07 Oncotherapy Science, Inc. TOMM34 peptides and vaccines including the same

Also Published As

Publication number Publication date
TW201414752A (zh) 2014-04-16
IL236690A0 (en) 2015-02-26
EP2895600A4 (en) 2016-05-04
AU2013317194B2 (en) 2018-07-12
BR112015004349A2 (pt) 2017-08-08
US11266729B2 (en) 2022-03-08
BR112015004349B1 (pt) 2022-11-01
CN107881158A (zh) 2018-04-06
SG10201701866QA (en) 2017-04-27
CA2873155C (en) 2022-07-26
CN107881158B (zh) 2021-11-16
US20180360938A1 (en) 2018-12-20
RU2663350C2 (ru) 2018-08-03
ES2784862T3 (es) 2020-10-01
EP2895600A1 (en) 2015-07-22
MX362912B (es) 2019-02-22
CA2873155A1 (en) 2014-03-20
HK1212730A1 (en) 2016-06-17
RU2015113436A (ru) 2016-11-10
CN104619833A (zh) 2015-05-13
JP2015529219A (ja) 2015-10-05
CN104619833B (zh) 2018-01-02
EP2895600B1 (en) 2020-02-19
AU2013317194A1 (en) 2015-02-05
WO2014041784A1 (en) 2014-03-20
US20150174223A1 (en) 2015-06-25
KR20150054710A (ko) 2015-05-20
DK2895600T3 (da) 2020-04-27
TWI632162B (zh) 2018-08-11
MX2015003017A (es) 2015-06-10
JP6283861B2 (ja) 2018-02-28
KR102110873B1 (ko) 2020-05-14
US10092634B2 (en) 2018-10-09
IL236690B (en) 2021-03-25
SG11201501761SA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
IL283139A (en) Proline-locked clamped peptides and their uses
SG11201500111VA (en) Peptides and uses thereof
SG11201501646PA (en) Peptides and their uses
PT2855506T (pt) Péptido e utilização do mesmo
SG10201707316WA (en) Kntc2 peptides and vaccines containing the same
IL245924A0 (en) topk peptides and components comprising them
EP2825548A4 (en) MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF
IL236690A0 (en) ube2t peptides and components containing them
IL228995A0 (en) b5sema peptides and components containing them
EP2872530A4 (en) KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
PT2809342T (pt) Péptido bifuncional
EP3049153B8 (de) Zyklische, amyloid-beta-bindende peptide und deren verwendung
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
ZA201303886B (en) Tomm34 peptides and vaccines including the same
EP2872531A4 (en) LY6K EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
IL237400B (en) Rhizobacteria and its uses
IL221474A0 (en) Hjurp peptides and vaccines including the same
ZA201207342B (en) Ect2 peptides and vaccines including the same
IL238788A0 (en) sema5b peptides and components containing them
ZA201504462B (en) TGFß-DERIVED POLYPEPTIDES AND USES THEREOF
IL225552A0 (en) wdhd1 peptides and vaccines containing them
IL225553A0 (en) 54orf18c peptides and vaccines containing them
EP2873676A4 (en) PEPTIDE WITH LOW MOLECULAR WEIGHT AND USE THEREOF
GB201214769D0 (en) Methodsa and peptides
IL215915A0 (en) Ttk peptides and vaccines including the same